PROCEPT BioRobotics (PRCT) to Release Quarterly Earnings on Wednesday

Key Points

• PROCEPT BioRobotics is set to release its Q2 2025 earnings data on August 6th, with analysts forecasting a loss of ($0.41) per share and a revenue of $75.67 million.
• The company's stock is currently valued at $53.73, having a market cap of $2.97 billion and a P/E ratio of -31.61.
• Insider trading activity shows significant selling, with a director recently selling 25,000 shares valued at over $1.5 million, resulting in a 63.51% decrease in their ownership.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $75.67 million for the quarter.

PROCEPT BioRobotics Stock Up 3.0%

PRCT traded up $1.45 on Friday, hitting $49.96. 1,284,652 shares of the company were exchanged, compared to its average volume of 1,189,216. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.75 and a current ratio of 8.95. The stock's fifty day moving average is $58.32 and its 200-day moving average is $59.73. The company has a market cap of $2.76 billion, a PE ratio of -29.39 and a beta of 1.05. PROCEPT BioRobotics has a 12 month low of $47.04 and a 12 month high of $103.81.

Analyst Ratings Changes

Several brokerages recently issued reports on PRCT. Truist Financial cut their target price on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, April 11th. Morgan Stanley lowered their target price on PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 15th. Oppenheimer assumed coverage on shares of PROCEPT BioRobotics in a research report on Monday, July 7th. They set a "market perform" rating on the stock. Stephens initiated coverage on PROCEPT BioRobotics in a research report on Wednesday, July 9th. They set an "overweight" rating and a $70.00 target price for the company. Finally, Bank of America lowered their price objective on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a research report on Friday, April 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, PROCEPT BioRobotics currently has an average rating of "Moderate Buy" and an average target price of $84.13.

Insider Activity

In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 25,000 shares of the stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $61.49, for a total transaction of $1,537,250.00. Following the completion of the sale, the director directly owned 14,363 shares in the company, valued at approximately $883,180.87. This trade represents a 63.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 100,000 shares of company stock valued at $6,271,250. 17.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its holdings in shares of PROCEPT BioRobotics by 7.3% in the first quarter. AQR Capital Management LLC now owns 18,892 shares of the company's stock valued at $1,101,000 after purchasing an additional 1,286 shares during the last quarter. Intech Investment Management LLC lifted its stake in PROCEPT BioRobotics by 54.4% in the first quarter. Intech Investment Management LLC now owns 28,389 shares of the company's stock valued at $1,654,000 after purchasing an additional 10,002 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in PROCEPT BioRobotics by 9.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company's stock worth $8,923,000 after buying an additional 13,767 shares during the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).